Ectin Research is managed by a core team of senior professionals from the pharmaceutical industry, clinical physicians and scientists from the academic world in a semi-virtual organization. Where a large network of external complementing competences is consulted when required.

Board of directors

  • Christer Edlund

    Christer Edlund, MD, PhD

    Chairman & co-founder

    Christer is chief physician in urology, region Halland, and he is the physician who was responsible for the treatment of the previously mentioned bladder cancer patient. Christer has broad cancer therapy experience from treating urology patients for many years and a substantial clinical network.

  • Anders Waas

    Board member

    Anders is business coach at GU Ventures. He has more than 30 years’ experience of global business development and product development in the pharmaceutical, biotech and medical technology industry e.g. Astra Zeneca, CV Therapeutics and WL Gore & Associates, as CEO of TikoMed and a large number of board positions.

  • Marie-Lois Ivarsson

    Marie-Lois Ivarsson, MD, Professor

    Board member & co-founder

    Marie-Lois is inspector and medical consultant at the Health and Social Care Inspectorate (IVO) and was former the operations manager and chief physician of the surgical clinic, region Halland. She runs a research laboratory at Sahlgrenska academy, university of Gothenburg. She has a significant academic network, extensive knowledge within the field of cancer treatment and has taken part in a number of larger clinical trials.

  • Peter Falk

    Peter Falk, PhD

    Board member & co-founder

    Peter is scientist at the Sahlgrenska academy, university of Gothenburg. He has wide experience of different experimental models and of methodological techniques for protein detection and a significant network in the scientific community.

  • Klementina Österberg

    Board alternate

    Klementina is CEO for GU Venture since 2007 and before that investment manager and marketing manager. She recently got rewarded to be “Årets Finansprofil 2019” by FinansKompetensCentrum. She has an extensive experience of developing and successfully investing in research ideas, which has led to that GU Venture is one of the top 20 companies of its kind in the world.

  • Hans Ivarsson

    Board alternate

    Hans is also board member of Ivarsson Medical Research AB and consults as senior finance executive. He is a retired finance specialist with a long experience from different roles in the finance industry.


  • Anna Sjöblom-Hallén, PhD, MBA


    Anna is an entrepreneur with extensive experience from her previous work as CEO, and as project manager of different start-ups in the Life Science field where she has managed to create profitable businesses. She has a broad network and knowledge of financing companies, conducting international out-licensing and from heading pharmaceutical development.

  • Steven Glazer, MD


    Steven is an experienced healthcare and biotech professional with extensive knowledge of research and development, medical and regulatory affairs. His background encompasses senior management and hands-on experience from pharmaceutical, biopharmaceutical, biotechnology and diagnostic industries in Europe and the United States. With previous positions such as Medical Director Novo Nordisk, Senior Vice President BioInvent, CMO Hansa Medical and current positions:  CMO RhoVac, CMO Idogen, Board Member, Immunicum, and Partner Ventac Partners.

Partnership opportunities

Ectin Research welcomes established companies in the oncology field in the discussion of potential commercial opportunities using the company’s proprietary technology.

For more information about the company and for the discussion of potential commercial opportunities please contact Anna Sjöblom-Hallén, CEO.